Can Liquid Biopsies and Tumor Biomarkers Personalize Prostate Cancer Treatment?
Experimental, minimally invasive “liquid biopsy” blood tests might soon help to personalize prostate cancer treatment by predicting androgen resistance and survival benefits from particular treatments.
MRI-Guided Triage Could Reduce Overdiagnosis in Localized Prostate Cancer
Use of multiparametric MRI could allow a significant portion of men with elevated PSA levels to avoid undergoing a biopsy without missing clinically significant prostate cancers.
Adding Carboplatin to Cabazitaxel Improves PFS in Aggressive Variant CRPC
Adding carboplatin to cabazitaxel was safe and associated with improved PFS among men with aggressive variant castration-resistant prostate cancer.
Hypofractionated RT Non-Inferior to Conventional RT in Prostate Cancer
A hypofractionated shorter course of radiotherapy was not inferior to a conventional regimen in men with localized prostate cancer.
Cabazitaxel No Better Than Docetaxel in Metastatic CRPC
Cabazitaxel at two different doses was no better than docetaxel with regard to OS or PFS in men with metastatic castration-resistant prostate cancer.
Intermittent Docetaxel Non-Inferior to Continuous Therapy in CRPC
An intermittent docetaxel regimen was non-inferior to continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer.
Docetaxel Does Not Worsen Long-Term QOL in Metastatic Prostate Cancer
The addition of docetaxel to ADT offered decreased QOL at 3 months vs ADT alone, but better QOL at 12 months, in metastatic hormone-sensitive prostate cancer.
By clicking Accept, you agree to become a member of the UBM Medica Community.